If you have a patient experiencing refractory angina and you’ve exhausted the standard of care, there is good news.
Lehigh Valley Heart and Vascular Institute has been chosen as one of only 16 sites to participate in the expansion phase of a clinical trial for an exciting new investigational product called XC001.
Produced by XyloCor Therapeutics, XC001 has been designed to promote revascularization around the heart. The hope is that new blood vessels will bypass diseased ones, improve blood flow and decrease recurring pain for anginas that are not responding to medication and stents, says Ronald Freudenberger, MD, Physician in Chief, Lehigh Valley Heart and Vascular Institute.
“XC001 is essentially a gene therapy. We’re delivering a gene the body already makes to the heart via direct injection in the hopes the person’s own heart cells will create more of a naturally existing protein in a process called gene transfer. It would be an incredible advance if we can show that it works,” Freudenberger says.